NFA
SLS icon

Nationwide Fund Advisors’s SELLAS Life Sciences SLS Stock Holding History

Nationwide Fund Advisors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4
Closed -$4K – 3254
2017
Q1 		$4K Hold
4
– – ﹤0.01% 3161
2016
Q4 		$12K Buy
+4
New +$23.3K ﹤0.01% 3109

Other funds holding SLS

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
ECM
Element Capital Management New York $3.2B AUM 29.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nationwide Fund Advisors's SLS Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of SELLAS Life Sciences (SLS) in Q2 2017, closing a stake of 4 shares — an estimated $4K sold.

Nationwide Fund Advisors first reported a position in SLS in Q4 2016 and held it in 2 quarters. The position peaked at $12K in Q4 2016. 34 funds tracked by Wall St. Rank hold SLS as of Q2 2017.

  • Nationwide Fund Advisors reported no remaining SELLAS Life Sciences position as of Q2 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 4 SELLAS Life Sciences shares in Q2 2017, an estimated $4K.
  • Nationwide Fund Advisors first reported a position in SELLAS Life Sciences in Q4 2016 and held it in 2 quarters.
  • Nationwide Fund Advisors's SELLAS Life Sciences position peaked at $12K in Q4 2016.
  • 34 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.